Search research articles
Contact Us
Filters
Showing results (601-610 of 616) with videos related to
Page
of 62
Sort By:
The Canadian Journal of Cardiology
|
May 10, 2022
Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease
, Beth L Abramson, Mohammed Al-Omran, et al.
The Lancet. Diabetes & Endocrinology
|
July 24, 2021
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
Mikhail N Kosiborod, Russell Esterline, Remo H M Furtado, et al.
Current Opinion in Cardiology
|
May 26, 2026
Superficial intercostal plane blocks for post-sternotomy pain control rationale and design for the EPOCH CardioLink-10 randomized clinical trial
Nitish K Dhingra, Fallon Dennis, Syed Mohammad Ali Hassan, et al.
The New England Journal of Medicine
|
September 1, 2020
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer, Stefan D Anker, Javed Butler, et al.
European Journal of Heart Failure
|
November 30, 2020
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
Stefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
The New England Journal of Medicine
|
August 27, 2021
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
JACC. Heart Failure
|
March 4, 2022
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial
Scott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
JAMA
|
March 29, 2020
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Mark C Petrie, Subodh Verma, Kieran F Docherty, et al.
The New England Journal of Medicine
|
September 20, 2019
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, et al.
The Canadian Journal of Cardiology
|
February 11, 2020
CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis
Eileen O'Meara, Michael McDonald, Michael Chan, et al.
Page
of 62
Search research articles
Search
Showing results (601-610 of 616) with videos related to
Sort By:
Page
of 62
The Canadian Journal of Cardiology
|
May 10, 2022
Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease
, Beth L Abramson, Mohammed Al-Omran, et al.
The Lancet. Diabetes & Endocrinology
|
July 24, 2021
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
Mikhail N Kosiborod, Russell Esterline, Remo H M Furtado, et al.
Current Opinion in Cardiology
|
May 26, 2026
Superficial intercostal plane blocks for post-sternotomy pain control rationale and design for the EPOCH CardioLink-10 randomized clinical trial
Nitish K Dhingra, Fallon Dennis, Syed Mohammad Ali Hassan, et al.
The New England Journal of Medicine
|
September 1, 2020
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer, Stefan D Anker, Javed Butler, et al.
European Journal of Heart Failure
|
November 30, 2020
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
Stefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
The New England Journal of Medicine
|
August 27, 2021
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
JACC. Heart Failure
|
March 4, 2022
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial
Scott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
JAMA
|
March 29, 2020
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Mark C Petrie, Subodh Verma, Kieran F Docherty, et al.
The New England Journal of Medicine
|
September 20, 2019
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, et al.
The Canadian Journal of Cardiology
|
February 11, 2020
CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis
Eileen O'Meara, Michael McDonald, Michael Chan, et al.
Page
of 62